Spero Therapeutics Inc Market Cap ($60.22 Million)
Market Cap & Net Worth: Spero Therapeutics Inc (SPRO)
Spero Therapeutics Inc market cap. Spero Therapeutics Inc (NASDAQ:SPRO) has a market capitalization of $60.22 Million ($60.22 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21013 globally and #4746 in its home market, demonstrating a -6.31% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Spero Therapeutics Inc's stock price $1.04 by its total outstanding shares 57901493 (57.90 Million). Also see SPRO cash flow conversion for how efficiently the company converts equity into cash flow.
Spero Therapeutics Inc Market Cap History (2017–2026)
Spero Therapeutics Inc market cap history from 2017 to 2026. Data shows change from $680.34 Million to $60.22 Million (-23.42% CAGR). Check SPRO stock price and chart for real-time trading data and today's change.
Index Memberships
Spero Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.00% | #594 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #2000 of 3165 |
Weight: Spero Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Spero Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Spero Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Spero Therapeutics Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.26x
Spero Therapeutics Inc's market cap is 2.26 times its annual revenue
Latest Price to Earnings (P/E) Ratio
15.74x
Spero Therapeutics Inc's market cap is 15.74 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $680.34 Million | $1.98 Million | -$46.10 Million | 343.78x | N/A |
| 2018 | $356.09 Million | $3.97 Million | -$41.66 Million | 89.79x | N/A |
| 2019 | $556.72 Million | $4.74 Million | -$60.17 Million | 117.40x | N/A |
| 2020 | $1.12 Billion | $9.33 Million | -$77.52 Million | 120.33x | N/A |
| 2021 | $927.00 Million | $3.07 Million | -$89.76 Million | 301.96x | N/A |
| 2022 | $100.17 Million | $48.58 Million | -$46.41 Million | 2.06x | N/A |
| 2023 | $85.12 Million | $103.78 Million | $22.81 Million | 0.82x | 3.73x |
| 2024 | $59.64 Million | $47.98 Million | -$68.57 Million | 1.24x | N/A |
| 2025 | $134.91 Million | $59.62 Million | $8.57 Million | 2.26x | 15.74x |
Competitor Companies of SPRO by Market Capitalization
Companies near Spero Therapeutics Inc in the global market cap rankings as of November 4, 2026. Also see SPRO asset base for a full breakdown of the balance sheet.
Key companies related to Spero Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Spero Therapeutics Inc (2017–2026)
Market capitalization of Spero Therapeutics Inc from 2017 to today. Between 2017 and today, Spero Therapeutics Inc's market cap moved from $680.34 Million to $ 60.22 Million, with a yearly change of -23.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $60.22 Million | -55.36% |
| 2025 | $134.91 Million | +126.21% |
| 2024 | $59.64 Million | -29.93% |
| 2023 | $85.12 Million | -15.03% |
| 2022 | $100.17 Million | -89.19% |
| 2021 | $927.00 Million | -17.43% |
| 2020 | $1.12 Billion | +101.66% |
| 2019 | $556.72 Million | +56.34% |
| 2018 | $356.09 Million | -47.66% |
| 2017 | $680.34 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Spero Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $60.22 Million USD |
| MoneyControl | $60.22 Million USD |
| MarketWatch | $60.22 Million USD |
| marketcap.company | $60.22 Million USD |
| Reuters | $60.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including … Read more